BeiGene Ltd. (BGNE)

NASDAQ: BGNE · IEX Real-Time Price · USD
188.04
-9.12 (-4.63%)
Aug 16, 2022 3:59 PM EDT - Market closed
-4.63%
Market Cap 19.52B
Revenue (ttm) 1.07B
Net Income (ttm) -2.01B
Shares Out 103.82M
EPS (ttm) -20.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 176,701
Open 195.09
Previous Close 197.16
Day's Range 187.43 - 197.62
52-Week Range 118.18 - 426.56
Beta 0.66
Analysts Buy
Price Target 440.79 (+134.4%)
Earnings Date Aug 4, 2022

About BGNE

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma;... [Read more...]

Industry Biotechnology
IPO Date Feb 3, 2016
CEO John Oyler
Employees 8,600
Stock Exchange NASDAQ
Ticker Symbol BGNE
Full Company Profile

Financial Performance

In 2021, BeiGene's revenue was $1.18 billion, an increase of 280.83% compared to the previous year's $308.87 million. Losses were -$1.41 billion, -11.49% less than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for BGNE stock is "Buy." The 12-month stock price forecast is 440.79, which is an increase of 134.41% from the latest price.

Price Target
$440.79
(134.41% upside)
Analyst Consensus: Buy
Stock Forecasts

News

BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company that is developing and commercializing ...

BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable He...

CAMBRIDGE, U.S. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology...

BeiGene Reports Second Quarter 2022 Financial Results

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company developing and commercializing in...

Why BeiGene (BGNE) Might Surprise This Earnings Season

BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in...

CAMBRIDGE, Mass., & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)---- $BGNE--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology biotechnology company focused on developing innovative an...

BeiGene Appoints Chan Lee as General Counsel

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology biotechnology company focused on developing and comm...

Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endomet...

Randomized Controlled First-Line Gastric Cancer Trial of DKN-01 plus tislelizumab and chemotherapy in collaboration with BeiGene Leap to host R&D Day today at 12:00 p.m. ET CAMBRIDGE, Mass.

Other symbols: LPTX

BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene announced it entered into a worldwide strategic collaboration with InnoRNA to develop mRNA-based therapeutics.

BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy i...

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)---- $BGNE #WCGIC2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on develop...

BeiGene, Ltd. (BGNE) Soars 15.5%: Is Further Upside Left in the Stock?

BeiGene, Ltd. (BGNE) witnessed a jump in share price last session on above-average trading volume.

Why Shares of BeiGene Popped Today

Regulators in China agreed to start the review process for one of its medicines.

BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab

CAMBRIDGE, Mass., & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and a...

BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and af...

BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and af...

BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Associati...

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and af...

China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing i...

BeiGene to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

CAMBRIDGE, Mass. & BEIJING & BASEL, Switzerland--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and af...

BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)---- $BGNE #cancerhasnoborders--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused o...

BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commerc...

BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress

CAMBRIDGE, Mass., BEIJING & BASEL, Switzerland--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene announced 20 presentations from the Company's global clinical development programs in hematologic malignancies...

BeiGene Reports First Quarter 2022 Financial Results

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commerc...

Why Earnings Season Could Be Great for BeiGene (BGNE)

BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

5 Large-Cap Stocks to Buy Ahead of Q1 Earnings This Week

Five large-cap companies with a favorable Zacks Rank will report first-quarter earnings results this week. These are: CI, HST, BGNE, VRTX and EOG.

Other symbols: CIEOGHSTVRTX

BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapse...

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing i...

BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey

HOPEWELL, N.J. & CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene announced the groundbreaking of its flagship U.S. manufacturing, clinical R&D center at the ...